Researchers set new safety limits for valproate, a drug tied to birth defects

Scientists have developed evidence-based reference values for how much valproate exposure during pregnancy poses developmental risks, using human data rather than animal studies. The work could reshape how regulators assess the epilepsy drug's safety profile and influence prescribing guidelines that affect millions of patients worldwide.

Originaltitel: Proposal for reference values for the developmental effects of valproate based on human data using a benchmark dose approach